Focused on developing novel formulations of traditional and psychedelic therapeutics
Silo Pharma Inc. is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including PTSD, stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. Through the acquisition and licensing of technology rights and IP from leading universities and researchers, Silo focuses on developing novel therapies that are conventional drugs and psychedelic formulations.
Get more information on Silo Pharma. Sign up for email alerts online.
Silo has licensed therapeutics that will allow the company to pursue the more streamlined 505(b)(2) route for trials.
Silo anticipates this strategy will lower cost and allow for a faster approval process to help patients with few if any proven addressable therapeutics. Exclusive collaborations with world-class medical research partners provide valuable IP, assets, and time-to-market advantages.
Growing pipeline
of opportunities
- Psychedelic drugs have shown encouraging promise
- Licensing and funding research with transformative potential
Targeting a breadth of therapies & potentially transformative assets
- Developing therapeutics for patients suffering from indications such as Alzheimer’s; Fibromyalgia; and Stress-Induced Psychiatric Disorders.
- Silo has partnered with leading academic institutions
Gaining regulatory support
- Silo has a faster FDA pathway utilizing 505(b)(2) pathway with various therapeutics in its pipeline
Valuable intellectual property
- Silo has been granted patent protection and has filed numerous IP patent applications
Development timelines and current drugs in the pipeline
Silo Pharma believes in following the science to identify the best application for a therapeutic by targeting indications with the biggest need, and selecting the best route of delivery for patents.
Our current assets have shown promise in a range of illnesses and diseases, including Alzheimer’s; Fibromyalgia; and Stress-Induced Psychiatric Disorders.